Eli Lilly has entered into an agreement to develop and commercialise novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.  Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies.  The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss.   Rznomics will conduct early-stage […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!